Can patients with aplastic anemia drink corn silk water?

Written by Zhang Xiao Le
Hematology
Updated on November 08, 2024
00:00
00:00

Patients with aplastic anemia can drink corn silk tea, but corn silk tea has no therapeutic effect on aplastic anemia. Aplastic anemia is caused by various causes and mechanisms leading to bone marrow failure, mainly characterized by decreased bone marrow hematopoietic function, decreased total blood cells, and the resulting anemia, bleeding, and infection syndrome. The pathogenesis of aplastic anemia is not clear, mainly due to immune abnormalities. The treatment is mainly the use of immunosuppressants such as cyclosporine and hematopoietic agents, primarily androgens. Corn silk tea does not have a therapeutic effect on the mechanisms of this disease.

Other Voices

doctor image
home-news-image
Written by Li Fang Fang
Hematology
49sec home-news-image

The main cause of aplastic anemia is.

The causes of aplastic anemia are considered to be of three types: abnormalities in hematopoietic stem cells, abnormalities in the bone marrow microenvironment, and abnormalities in immune factors. Among these, abnormalities in immune factors play a dominant role. Therefore, most patients with aplastic anemia see some improvement after receiving immunosuppressive therapy clinically. However, there is a small subset of patients with aplastic anemia for whom immunosuppressive therapy is not effective, and the causes of the disease in these patients are not well understood and may be congenital, such as congenital dyskeratosis.

doctor image
home-news-image
Written by Li Fang Fang
Hematology
39sec home-news-image

Aplastic anemia is caused by how?

Aplastic anemia currently still has an uncertain etiology. However, clinical observations have suggested that chemotherapy drugs, viral infections, and radiation exposure might be related to the occurrence and development of aplastic anemia. Regardless of the cause, these factors all involve abnormalities in immune function. Abnormal immune function leads to the occurrence and development of aplastic anemia. Therefore, immunosuppressive therapy is often effective for patients with aplastic anemia in clinical settings. (Medication use should be conducted under the guidance of a professional doctor.)

doctor image
home-news-image
Written by Li Fang Fang
Hematology
52sec home-news-image

Is aplastic anemia serious?

Whether aplastic anemia is severe depends on the specific circumstances of the aplastic anemia. Aplastic anemia can be divided into acute aplastic anemia and chronic aplastic anemia. Among them, acute aplastic anemia has a sudden onset, more severe clinical symptoms, and a higher mortality rate, so it is relatively more severe. Chronic aplastic anemia has a slower onset, and the degree of decrease in blood cells is relatively mild, also making it less severe. However, in cases of acute aplastic anemia, if intensive immunotherapy is administered, the effectiveness can reach 60%-70%, and it can be cured through hematopoietic stem cell transplantation.

doctor image
home-news-image
Written by Li Fang Fang
Hematology
48sec home-news-image

Can aplastic anemia be cured completely?

Aplastic anemia clinically is categorized into acute aplastic anemia and chronic aplastic anemia. Acute aplastic anemia appears suddenly and is severe, with a short survival period. Chronic aplastic anemia develops slowly, has a longer history, and is relatively milder in condition. Whether it is acute aplastic anemia or chronic aplastic anemia, curative treatment can only be achieved through allogeneic hematopoietic stem cell transplantation. Although allogeneic hematopoietic stem cell transplantation offers a potential cure for aplastic anemia, there is also a certain rate of failure. Additionally, post-transplant, there is a presence of immune rejection.

doctor image
home-news-image
Written by Li Fang Fang
Hematology
45sec home-news-image

What causes aplastic anemia?

Aplastic anemia's exact causes are still not completely clear. Clinically, it is believed that immune dysfunction is a significant factor associated with aplastic anemia. Most cases of aplastic anemia can achieve good therapeutic outcomes through immunosuppressive treatment, which indirectly supports this view. However, some scholars believe that in aplastic anemia, there are patients for whom immunosuppressive treatment is ineffective. This suggests that other factors might exist, such as congenital anomalies in hematopoietic stem and progenitor cells, or abnormalities in the hematopoietic microenvironment, which may also play a role in the development of aplastic anemia.